You are here: Industry Insights > Parkinson's

News List

GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease WorldPharmaNews
December 06, 2021
GlaxoSmithKline plc and the University of Oxford announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine. The new Institute, which will be based at the University of Oxford, aims to...
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's prnasia
August 05, 2021
Alterity Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Alterity's patent application No. 17/239,375.
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's prnasia
July 02, 2021
Alterity Therapeutics has announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).
AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson's Disease prnasia
May 28, 2021
AffaMed Therapeutics, a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced that China's National Medical Products Administration ...
ATH434 protects brain cells and improves motor function in Parkinsonian disorder prnasia
April 22, 2021
Alterity Therapeutics announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) ...
Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson's disease with the US FDA prnasia
March 24, 2021
Forest Hills Partners Hong Kong, S.A.R., China Limited (also known as Forest Hills Lab) is ready to file an Investigative New Drug (IND) application with the US FDA in April 2021 to assess tolerability and efficacy with one of its drug candidates, namely
IRICoR, Université de Montréal, IRIC and Valence Discovery to Design Parkinson's Disease Candidates americanpharmaceuticalreview
March 17, 2021
IRICoR and Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery announced a collaboration focused on the discovery of novel drug candidates for the treatment of ...
Mitokinin Enters into Purchase Agreement with AbbVie americanpharmaceuticalreview
March 08, 2021
AbbVie has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
AbbVie Opts to Acquire Mitokinin contractpharma
March 03, 2021
Following completion of IND enabling studies on Mitokinin's lead PINK1 compound for Parkinson's disease.
Blackfynn Builds Therapeutic Pipeline with Option to a Phase 3-Ready Drug for Parkinson's americanpharmaceuticalreview
February 23, 2021
Blackfynn has entered into an agreement with an undisclosed partner to acquire rights to a Phase 3-ready drug to treat Parkinson's.

Previous page 1 2 3 Next page